Abstract:

Objective To explore the clinical value of single-day combined Pyridostigmine Bromide and clonidine test on short stature (SS) children. Methods The children (n=125) presenting with SS visiting the Department of Pediatric Internal Medicine, Weifang People's Hospital from June 2019 to June 2021 were selected, and they were randomized into two groups. Pyridostigmine Bromide and clonidine provocation test was implemented for children in the experimental group, the single-day combined arginine and clonidine test was implemented for children in the control group. Growth hormone (GH) was tested by the chemiluminescence method. The positive rate and incidence of adverse reactions of GH deficiency between two methods were compared to evaluate the efficacy and safety of GH provocation test. Results The average GH peak level for provocation test in two groups was (17.44±5.56)μg/L and (17.88±5.60)μg/L, respectively, no difference was statistically significant (P>0.05). Differences in GH peak positive rate and adverse reaction rate between two groups weren't statistically significant (all P>0.05). Conclusion The outcome of combined Pyridostigmine Bromide and clonidine provocation test is highly consistent with that of the combined arginine and Alonidine provocation test, it is eligible to be used to evaluate GH level in SS children, and it is identified as a simple and effective test method.

Key words: growth hormone deficiency, growth hormone stimulation test, pyridostigmine bromide, clonidine, arginine, short stature